GlycoMark Updates for Healthcare Professionals Caring for Patients with Diabetes
Biomarkers and Diabetes Issue 20 - August/September 2019
Biomarkers and Diabetes
Know both your numbers Dear Healthcare Professional,

In this issue of The MARK, we spotlight biomarker utility in managing patients with diabetes.

Up to 40% of patients with an A1C < 7% experience postprandial hyperglycemia and glycemic variability.1,2
Over 15% of A1C results can be affected by hematology conditions, medications, drugs, medical therapies, diseases, and other factors3
Factors Known To Alter A1C3
Specifically indicates recent hyperglycemia and hyperglycemic excursions (1 to 2 weeks)4
More robustly reflects glycemic excursions, often in the postprandial state, than A1C5
Identifies patients that may benefit from . . . <Read More>
Factors known to alter A1C...
Quickly, Easily Educate Your Patients on the GlycoMark Test!
Request Printed Copies
The GlycoMark test complements other tests for diabetes for a more complete assessment of glycemic control. The GlycoMark test can help you identify recent hyperglycemia and hyperglycemic excursions.glycemia and hyperglycemic excursions
How to Order the GlycoMark Test:
LabFinder The GlycoMark test is available through numerous national and regional laboratories, and through LabFinder®. Contact your preferred laboratory for information or download the NEW GlycoMark Test Ordering Guide to identify a laboratory and corresponding test codes.

The GlycoMark Test is reimbursed by most federal, state and private payers, CPT 84378.

To order test kits for your laboratory, please refer to our online resources and contact us! We are happy to help support you in setting up the test on any open channel chemistry platform.
1Erlinger TP, Brancati FL. Diabetes Care. 2001 Oct;24(10):1734-8. 2Bonora E, et al. Diabetologia. 2006 May;49(5):846-54. 3Hirsch IB, et al. Diabetes Technol Ther. 2012 Nov;14(11):973-83; quiz 983. 4Dungan KM. Expert Rev Mol Diagn. 2008 Jan;8(1):9-19.
5American Diabetes Association. Medical Management of Type 2 Diabetes, 7th edition. 2012.

The Mark newsletter is distributed to healthcare professionals that treat and manage patients with diabetes, and contains the latest updates and important references for the GlycoMark test. This is a complimentary publication provided through the generous support of GlycoMark, Inc

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.

The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to diagnose disease or identify patients that will experience complications of diabetes or the likelihood of experiencing complications.

The information above contains general reimbursement information only and is not legal advice, nor is it advice about how to code, complete, or submit any claim for payment. Providers have the ultimate responsibility for all aspects of coding and billing.

GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo. All other trademarks cited herein are the property of their respective owners. © 2019 GlycoMark, Inc. All Rights Reserved. M-90-1A
805 Third Avenue, 17th Floor, New York, NY 10022
1-888-744-0221 - -